Orthocell Ltd · ASX:OCC
Orthocell — Shareholder Meeting (November 2025)
44 slides from Orthocell's shareholder meeting presentation, November 2025
Slide 1: AGM Presentation
AGM Presentation Paul Anderson Orthocell CEO and MD November 2025
Slide 2: Disclaimer
Disclaimer This presentation prepared by Orthocell Ltd (“Company”) does not constitute, representations contained in this presentation, and they do not accept any or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy liability whatsoever (including in negligence)
Slide 3: Orthocell at a glance
Orthocell at a glance Australian medical device company with growing international revenue and US market launch of its flagship nerve repair product, Remplir Best In Class Products Approved Manufactured In Australia In Nine Jurisdictions Scaled facility certified to manufacture in major jurisdiction
Slide 4: Orthocell 3-year vision
Orthocell 3-year vision Business goal Be at the forefront of regenerative medicine innovation, advancing toward ASX 300 inclusion through disciplined growth and a sustainable, well-funded product pipeline. Strategic focus Win in the Advance our Continue growth Build global Americas in ANZ & Asia foo
Slide 5: FY26 Commercial Focus
FY26 Commercial Focus • Effective launch of Remplir in the US, delivering on our commitments • Strategic Asia expansion focused on high-return Remplir markets • Complete UK & EU launch planning post-Q2 submission for FY27 entry • Recruit specialist talent to deepen expertise and enable scalable grow
Slide 6: Orthocell's Flagship Product: Early adoption commenced
Early adoption commenced - Momentum to build in Dec Quarter and grow in 2H FY26 Surgical use into US$1.6 billion total addressable market1 has commenced within 3 months of achieving US Orthocell’s FDA 510(k) clearance. Low volumes initially to build surgical familiarity with a view to momentum and s
Slide 7: Orthocell's Flagship Product: Early adoption commenced
Early adoption commenced - Momentum to build in Dec Quarter and grow in 2H FY26 Surgical use into US$1.6 billion total addressable market1 has commenced. >60 surgeries completed over Orthocell’s the last 4 months. Low volumes initially to build surgical familiarity with a view to momentum and sales
Slide 8: Highly Credentialed Board
Highly Credentialed Board Recent appointments of John Van Der Wielen and Professor Fiona Wood AM places Orthocell in a strong position to drive its products into global markets and accelerate revenue growth Mr John Van der Wielen Mr Paul Anderson Dr Ravi I. Thadhani Professor Fiona Wood AM Mr Michae
Slide 9: Growing Revenue
Growing Revenue Record revenue of $3.0 million achieved for the quarter ended 30 September 2025 representing the sixth consecutive quarter of record revenue. Outstanding result does not yet include material revenue from Remplir sales in the US, which are expected to build during the December 2025 Qu
Slide 10: Nerve repair made SMRT
Nerve repair made SMRTTM Remplir is engineered with Orthocell’s proprietary SMRT technology to help patients TM reclaim touch, movement, and their lives.
Slide 11: Nerve repair, made SMRT
Nerve repair, made SMRT Collagen nerve wrap used in the repair of peripheral nerve injuries. It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing Guiding predictable outcomes in peripheral nerve repair Mimics the natural Creates an optimal E
Slide 12: Indications
Indications Remplir is a highly versatile product that CONNECT delivers a single solution for either Enables tensionless repair of transected nerve connecting severed nerves, protecting injuries, supporting direct repairs with or damaged nerves or capping amputated without grafts, as well as nerve t
Slide 13: US Peripheral Nerve Repair Trends
US Peripheral Nerve Repair Trends Suturing is still the most commonly performed procedure and considered to be the “gold standard” technique for peripheral nerve repair Over 700,0001 peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method. Suturing • Technicall
Slide 14: Significant US Market Opportunity
Significant US Market Opportunity Orthocell has commenced commercial distribution into an estimated US$1.6 billion total addressable nerve repair market1 in the US alone Remplir is not seeking to replace a current dominant market incumbent. Devices are only used in ~10% of procedures. Current device
Slide 15: US Commercialisation Platform
US Commercialisation Platform Well positioned…. Manufacturing Logistics / Shipping US Market Roll Out Existing GMP facility in place US based central Internal Sales and Med in Western Australia warehousing, order Ed team combined with fulfillment, customer service external Distributor Network 4,000
Slide 16: Manufacturing / Product Supply
Manufacturing Manufacturing / Product Supply Capacity in place to deliver the volumes through to company profitability • Annual medical device production capacity of 100,000 units in place at certified GMP facility in Western Australia • Already in production for Australia, New Zealand, Singapore, U
Slide 17: Logistics / Shipping
Logistics / Shipping Logistics / Shipping On the ground logistics in the US to deliver into early sales orders • Stable product for shipping, no temperature control required • Initial inventory of 4,000 units in place, shipped from Australia • Stock warehoused at Uniphar’s GMP certified 65,000 squar
Slide 18: US based experienced sales executive
US based experienced sales executive US-based sales executive driving the market launch and sales of Remplir John Walker Vice President-Sales John Walker East Coast Sales West Coast Sales Vice President – Sales Director Director Mr Walker is a highly experienced sales executive, who has successfully
Slide 19: Path to sales ramp up
Path to sales ramp up Distributor network and surgeon engagement ahead of schedule. Surgical use growing. On track for sales ramp up in 2H FY26 FY26 Targets Status Ahead of schedule - 25 States covering 40% of 1. Distributor network: >40% ofDistributor Network US population coverage population 2. Su
Slide 20: Promising New Application in Prostate Cancer Surgery
Promising New Application for in Prostate Cancer Surgery Surgeons are using Remplir in prostate surgery to preserve nerve function and improve functional recovery. Potential significant expansion of the Total Addressable Market. Initial patient data expected Q4 CY25. • Australian urologists are usin
Slide 21: Pipeline
Pipeline Advanced product portfolio with near term milestones and emerging pipeline. Orthocell is working with a US adviser to secure a partner to accelerate the commercialisation of the tendon cell therapy. Multi-Billion Product Status Next Steps US Markets Medical Devices >500,000 Tendon repair Su
Slide 22: Upcoming Catalysts
Upcoming Redefining nerve repair Catalysts1 US FDA market clearance and Pre-Launch Achieved Appoint initial US distributors Achieved HKG product registration Achieved US first surgical use Achieved US first sales Achieved Appoint further US sales team members Achieved Appoint first & second distribu
Slide 23: Investment Highlights
Investment Highlights Commercial-stage Product margins Strengthened board Best in class products ~$50M cash at bank, medical device retained in-house with the appointments for Bone, Nerve and strengthened share company at revenue Manufacturing facility of highly experienced Tendon repair register, s
Slide 24: Authorised for release by Paul Anderson
Authorised for release by Co-Founder and Managing Director, Paul Anderson Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com
Slide 25: Questions
Questions
Slide 26: Notice of Annual General Meeting & Resolutions
Notice of Annual General Meeting & Resolutions
Slide 27: Voting Instructions
Voting Instructions
Slide 28: Proxy Voting
Proxy Voting
Slide 29: Registration
Registration G Preferred name: Ethan Brown ¢ © Key Documents D Ask a Question G Submit Votes 4g AUTOMIC GROUP™ Voting Instructions Once registered and voting has opened, click on the “Voting” dropdown Select either the “Full” or “Allocate” and then your voting direction for each resolution Follow th
Slide 30: Ask a Question
DP Ask a Question My Questions [A texrauestion | Q versat question 4g AUTOMIC GROUP™ Ask a Question Click on the “Ask a Question” dropdown, then “Ask Question” Choose Text Question or Verbal Question Type your question then select the relevant resolution and holding/capacity. Once done click “Submit
Slide 31: Resolutions
Resolutions
Slide 32: Resolution 1 - Adopt Remuneration Report
Resolution 1 - Non-Binding Resolution to adopt Renumeration Report Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 33: Resolution 2 - Re-election of Michael McNulty
Resolution 2 - Re-election of Mr Michael McNulty as a Director Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 34: Resolution 3 - Approval of Employee Awards Plan
Resolution 3 - Approval of Employee Awards Plan Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 35: Resolution 4 - Increase in Non-Executive Directors' cash fees
Resolution 4 - Increase in Non-Executive Directors’ cash fees Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 36: Resolution 5 - Fee Share to John Van Der Wielen
Resolution 5 - Issue of Fee Share to Mr John Van Der Wielen or his nominee(s) Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 37: Resolution 6 - Fee Share to Dr Ravi Thadhani
Resolution 6 - Issue of Fee Share to Dr Ravi Thadhani or his nominee(s) Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 38: Resolution 7 - Fee Share to Professor Fiona Wood
Resolution 7 - Issue of Fee Share to Professor Fiona Wood or her nominee(s) Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 39: Resolution 8 - Fee Share to Michael McNulty
Resolution 8 - Issue of Fee Share to Mr Michael McNulty or his nominee(s) Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 40: Resolution 9 - Amendment of the Constitution
Resolution 9 - Amendment of the Constitution Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 41: Resolution 10 - Short-Term Performance Rights to Paul Anderson
Resolution 10 - Issue of Short-Term Performance Rights to Mr Paul Anderson or his nominee(s) Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 42: Resolution 11 - Termination benefits for Paul Anderson
Resolution 11 - Approval of potential termination benefits to Mr Paul Anderson in relation to Short-Term Performance Rights Proxy Position FOR AGAINST OPEN ABSTAIN Votes at Chair’s Discretion – Orthocell | AGM Presentation
Slide 43: Voting
Voting
Slide 44: Thank you for attending
Thank you for attending